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Abstract
Transforming growth factor β (TGF-β) signaling pathway plays important roles in many biological
processes, including cell growth, differentiation, apoptosis, migration, as well as cancer initiation and
progression. SMAD4, which serves as the central mediator of TGF-β signaling, is specifically
inactivated in over half of pancreatic duct adenocarcinoma, and varying degrees in many other types
of cancers. In the past two decades, multiple studies have revealed that SMAD4 loss on its own does
not initiate tumor formation, but can promote tumor progression initiated by other genes, such as
KRAS activation in pancreatic duct adenocarcinoma and APC inactivation in colorectal cancer. In
other cases, such as skin cancer, loss of SMAD4 plays an important initiating role by disrupting DNA
damage response and repair mechanisms and enhance genomic instability, suggesting its distinct
roles in different types of tumors. This review lists SMAD4 mutations in various types of cancer and
summarizes recent advances on SMAD4 with focuses on the function, signaling pathway, and the
possibility of SMAD4 as a prognostic indicator.
Key words: TGF-β, SMAD4, tumorigenesis, prognosis, mouse model

Introduction
The transforming growth factor-beta (TGF-β)
superfamily contains over forty members, including
TGF-βs, Nodal, Activin, and bone morphogenetic
proteins (BMPs) [1, 2]. TGF-β/SMAD4 signaling
pathway controls the signal transduction from cell
membrane to nucleus, and is responsible for a wide
range of cellular processes, including proliferation,
differentiation, apoptosis, migration, as well as cancer
initiation and progression [3]. TGF-β protein has dual
functions on tumorigenesis where it exhibits a
suppressive role by inducing cell cycle arrest and
apoptosis at early stages of tumor formation. Later on,
with tumor progression, tumor cells gradually
become insensitive to it, and secreted TGF-β protein
enhances tumor immunosuppression and facilitates
tumor angiogenesis, invasion and metastasis [1]. As
the core mediator of canonical TGF-β signaling
pathway, SMAD4 plays a pivotal role in the switch of
TGF-β function on tumorigenesis. Although the

TGF-β/SMAD4 pathway is relatively simple, it can be
regulated extensively by numerous classical
pathways, such as MAPK, PI3K/AKT and
WNT/β-catenin, to form a complex network [1, 4].
Here, we will review TGF-β/SMAD4 function, its
related signaling network, and the impact of SMAD4
mutation on cancer.

Structure of SMAD4
SMAD4 gene consists of 12 exons and 10 introns.
At first, only 11 exons were identified, and another
exon was discovered years later upstream of exon 1,
and was therefore named exon 0 [5, 6]. The protein
encoded by this gene is composed of 552 amino acids,
with a molecular weight of 60 KD. The primary
structure of SMAD4 protein consists of three major
parts, including the N-terminal MH1 domain, the
C-terminal MH2 domain and the linker region
between them (Figure 1A) [7]. The MH1 domain is
http://www.ijbs.com
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responsible for DNA binding by recognizing the
SMAD-binding DNA element (SBE) [8], while the
MH2 domain is important for its transcriptional
activity [9-11], and can interact directly with the MH1
domain of other SMAD proteins [12]. The SMAD
activation domain (SAD), locating at the C-terminal of
linker region, is necessary for SMAD4 transcriptional
activity [9].

The role of SMAD4 in TGF-β signaling
pathway
SMADs are a group of proteins transducing
extracellular signals directly to the nucleus. There are
eight different SMADs in mammalian cells, which can
be divided to three categories: (1) the receptorregulated SMAD (R-SMAD) including SMAD1,
SMAD2, SMAD3, SMAD5, and SMAD8/9. While
SMAD2/3 mainly mediate signaling from TGF-β
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subfamily members, SMAD1/5/8 transduct signaling
from bone morphogenic protein (BMP) subfamily
members; (2) the common-mediator SMAD
(Co-SMAD) including only SMAD4, which is the
central mediator of both TGF-β and BMP signaling
pathway; and (3) the inhibitory SMAD (I-SMAD)
including SMAD6 and SMAD7, which mainly
function to inhibit receptor mediated R-SMAD
phosphorylation, thus preventing the complex
formation with Co-SMAD [13] (Figure 1B). Because
many members in both TGF-β and BMP subfamilies
play many important roles in various cancers, it is out
of scope to describe specific functions of members in
each of these subfamilies, therefore we will use
TGF-β/SMAD4 to represent SMAD4 mediated
signaling of the superfamily with an emphasis on
signaling of TGF-β subfamily members.

Figure 1. The structure of SMAD4 and its role as the common mediator for signaling of TGF-β superfamily. (A) Diagrammatic representation
of the structure of SMAD4. Abbreviations: NLS, nuclear localization signal; NES, nuclear export signal; SAD, SMAD activation domain; SBE, SMAD binding DNA
element. (B) Diagram showing SMAD4 as the common mediator for TGF-β and BMP signaling. TF: transcriptional factor.
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Figure 2. Schematic diagram of the interaction between TGF-β/SMAD4 signaling pathway and MAPK (mitogen-activated protein kinase),
PI3K/AKT (phosphatidylinositol-3 kinase/AKT) and WNT/β-catenin pathways. The canonical TGF-β/SMAD4 signal initiates from the TGF-β ligand
activation and its binding to the type II and I receptors (T-βR II and T-βR I), which then phosphorylates SMAD2/3. The phosphorylated SMAD2/3 form a
heterodimeric complex with SMAD4 and translocate to the nucleus and bind to SBE directly and regulate target genes transcription with the help of transcriptional
factors. These target genes are mainly involved in growth arrest and apoptosis. (A) RAS/RAF/ERK1/2 axis regulates the TGF-β/SMAD4 pathway by (1)
phosphorylating SMAD2 and SMAD3 to prevent its translocation into the nucleus; (2) mediating SMAD4 degradation; and (3) promoting AP-1 complex formation at
the TGF-β1 promoter, thus boost the TGF-β1 transcription and secretion. As the substrate of JNK, c-Jun can directly bind to the transcriptional corepressor
TG-interacting factor (TGIF) to inhibit SMAD2 dependent transcription. P38 can phosphorylate SMAD binding partners, such as activating transcription factor-2
(ATF-2), in nucleus and therefore facilitates TGF-β/SMAD4 induced genes transcription. (B) PI3K/AKT pathway suppresses the T-βR I mediated SMAD3
phosphorylation through its downstream molecule mTOR. AKT can directly phosphorylate FOXO and keep it in the cytoplasm to prevent its binding to the
promoter of p27 and p21, thus blocks the TGF-β/SMAD4 mediated cytostatic signals. (C) β-catenin destruction complex consisting of AXIN, APC, GSK3β and CKIα
causes SMAD7 ubiquitination and degradation. And in turn, SMAD7 can disassemble the complex by binding to AXIN, hence stablize β-catenin and promote its
nucleus translocation.

TGF-β subfamily signaling initiates from TGF-β
ligand activation and its binding to the type II
receptor (T-βR II). T-βR II then recruits and
phosphorylates the type I receptor (T-βR I), which in
turn phosphorylates its downstream target
SMAD2/3. SMAD2/3 are phosphorylated at their
conserved C-terminal SSXS motif (S is serine and X is
any amino acid), leading to a conformational change
in MH2 domain and its subsequent dissociation from
the receptor [14]. Thereafter, the phosphorylated
SMAD2/3 form a heterodimeric complex with
SMAD4, and subsequently translocates to the nucleus
[13, 15], where it binds to SBE directly and recurits
co-transcriptional factors to transactivate or repress
target genes [16].
The
canonical
TGF-β/SMAD4
signaling
pathway plays a tumor suppressive role at early
stages, mainly by inducing cell cycle arrest and
apoptosis. SMAD4 functions at the G1/S checkpoint

to make cells stay at the G1 phase, thus leading to cell
cycle arrest [17]. Some CDK inhibitors, like p15, p21
and p27, are involved in this process [18]. For
example, SMAD2/3/4 form a complex with
transcriptional factor FoxO to promote transcription
of p15 and p21. When ectopic overexpression of
SMAD4 is induced in SMAD4-negative cells, it can
bind to the promotor of p21 and enhance its
transcription [19]. Inversely, TGF-β cannot induce the
expression of p21 in pancreatic cancer cell lines, which
lack SMAD4, with the result that cell growth is out of
control [20]. Additionally, Lecanda et al. (2009) found
that TGF-β/SMAD4 signal can enhance p27
expression, whereas inhibition of p27 by siRNA
blocks the TGF-β/SMAD4 related cell growth arrest
[21].
The nucleus localized SMAD2/3/4 complex
induces apoptosis by promoting pro-apoptotic genes
expression, such as TIEG (TGF-β-inducible early
http://www.ijbs.com
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response gene), DAPK (the death-associated protein
kinase), GADD45β and Bim. It was shown that
expression of TIEG induced by TGF-β signaling
causes apoptosis in pancreatic epithelial cells [22]. The
rest three genes were reported to induce cytochrome
C release from mitochondria and cause caspase
activation [23-25].

Crosstalk with other pathways
In the past two decades, increasing number of
classical pathways has been reported to interact with
the canonical TGF-β/SMAD4 pathway. These
crosslinks are along the whole TGF-β/SMAD4 signal
transmision chain, from SMAD2/3 phosphorylation,
SMAD complex formation, its translocation to nucleus
and transcriptional activity. Here we will summarize
the interaction between TGF-β/SMAD4 pathway
with some well-established pathways including, but
not limited to, MAPK (mitogen-activated protein
kinase),
PI3K/AKT
(phosphatidylinositol-3
kinase/AKT) and WNT/β-catenin pathways.

MAPK pathway
MAPK is a superfamily that transduces
extracellular signals to nucleus rapidly to regulate
genes transcription, and affects a wide range of
cellular processes including cell proliferation,
differentiation and apoptosis. MAPK consists of three
principal subfamilies: (1) the extracellular signal
regulated kinase (ERK1/2); (2) c-Jun N-terminal
kinase (JNK1/2/3) and (3) P38/MAPKs [26]. These
subfamilies can phosphorylate a set of proteins to
alter cell behaviors, and in verse, they can be activated
by multiple extracellular molecules, such as TGF-β
cytokines [27].

ERK pathway
ERK pathway is mainly responsible for cell
growth and survival [28]. It can be activated by the
RAS/RAF/MEK1/2 axis propagated signal that is
initiated by membrane-associated receptor tyrosine
kinases (RTKs) [29]. TGF-β peptide can mediate ERK
activation rapidly in normal epithelial cells and in
cancer cells [30]. It has been demonstrated that this
regulation depends on the T-βR I recruited and
activated ShcA/Grb2/Sos complex, which subsequently activate RAS/RAF/MEK1/2 signal [31, 32].
Inversely, ERK pathway inhibits the TGF-β/SMAD4
pathway by phosphorylating SMAD2 and SMAD3 at
the serine or threonine residues in the linker region,
thus preventing its translocation into the nucleus [33].
Subsequently, Matsuura et al. (2005) identified ERK
phosphorylation sites in SMAD3 at Thr178, Ser203,
and Ser207 in lung epithelial cells [34]. The TGF-β
activated RAS/ERK cascade also promotes AP-1
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complex formation at the TGF-β1 promoter, thus
boosting the TGF-β1 transcription and secretion [35].
SMAD7, as the inhibitory SMAD, can be upregulated
by ETS transcription factor ER81 through the
HER2/Neu/ERK pathway in breast and ovarian
cancer cell lines [36]. However, SMAD7 transcription
is negatively regulated by ERK cascade in normal rat
kidney (NRK) fibroblasts, suggesting the cell type
dependence.

JNK pathway
JNK, as a stress-induced kinase, is responsive to
various stress stimuli and is responsible for multiple
cellular activities such as proliferation and apoptosis
[37]. Principally, T-βR I can interact with TRAF6 and
cause its autoubiquitylation, which subsequently
activates TAK1 and JNK pathway [38]. Inversely, JNK
is implicated to reduce the secretion of TGF-β1, as
upon JNK inactivation, RAS gains ability to induce
TGF-β1 autocrine [39]. JNK can also mediate
phosphorylation of SMAD3 in the linker region and
facilitate its activation by T-βR I, as well as nuclear
translocation [40]. SMAD2 is another target of JNK, as
it has been demonstrated that C-Jun, the substrate of
JNK, can directly bind to the transcriptional
corepressor TG-interacting factor (TGIF) to inhibit
SMAD2 dependent transcription [41].

P38
Like JNK, p38 is also a stress-induced kinase that
activated by various stress stimuli and accounts for
diverse cellular processes. p38 can also be induced by
TGF-β via T-βR I-TRAF6 interaction and TAK1
activation [38], and TGF-β induced P38 activation can
strongly enhance SMAD4 sumoylation by PIAS
family of E3 ligase, thus facilitating SMAD4
dependent transcription [42]. In human breast cancer
cell line, SMAD2/3, phosphorylatd at Ser203/207 by
Rho-dependent kinase (ROCK) and p38, synergize
with TGF-β to induce cell growth arrest [43]. Apart
from the crosstalk in cytoplasm, p38 also
phosphorylates SMAD binding partners in nucleus
and therefore affects TGF-β/SMAD4 induced genes
transcription. For example, as the nuclear target of
p38, activating transcription factor-2 (ATF-2) could be
phosphorylated and bind to SMAD4 to activate TGF-β
induced transcription [44].

PI3K/AKT pathway
PI3K/AKT pathway is an intracellular signaling
pathway that is usually related to cell proliferation
and apoptosis inhibition, and is important for the
initiation and progression of many malignancies [45].
Upon activation of RTKs by a ligand, PI3K is activated
and converts phosphatidylinositol-4,5-bisphosphate
(PIP2) to phosphatidylinositol-3,4,5-triphosphate
http://www.ijbs.com
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(PIP3), which then phosphorylates and activates AKT,
and makes it localize on the plasma membrane [46].
The tumor suppressor PTEN can counteract PI3K and
thereby alleviate AKT activation [47].
A multitude of studies have indicated that
PI3K/AKT pathway is involved in TGF-β/SMAD4
pathway regulation. In mammary epithelial cell
NmuMG, TGF-β1 administration induces AKT
phosphorylation at Ser473 immediately, and
transfection of dominant negative Rho inhibits this
process [48]. Inactivating PI3K/AKT pathway by
inhibitors affects TGF-β mediated EMT and cell
migration [48]. This process is also affected by the
TGF-β1 induced miR-487a overexpression, which
directly binds to MAGI2 (Membrane-associated
guanylate kinase inverted 2), and then stabilizes
PTEN and suppresses PI3K/AKT pathway [49].
SMAD3 has been demonstrated to be the target of
PI3K/AKT to affect TGF-β/SMAD pathway.
Overexpression of AKT suppresses the T-βR II
mediated SMAD3 phosphorylation, while the SMAD2
is not affected [50]. Treatment with rapamycin to
activate the mammalian target of rapamycin (mTOR),
which is the downstream of AKT, can suppress
SMAD3 phosphorylation and activation [50].
Meanwhile, PI3K/AKT can also regulate SMAD3
function
by
phosphorylating
some
nuclear
transcriptional factors, such as FOXO. AKT can
directly phosphorylates FOXO and keep it in the
cytoplasm [51]. Once dephosphorylated, FOXO enters
the nucleus and binds to the promoter of p27 and p21
as a transcriptional factor, thus facilitating the
TGF-β/SMAD4 mediated cytostatic signals [52].

WNT/β-catenin pathway
WNT is a type of secretory protein that initiates
WNT/β-catenin signal from cell membrane to
nucleus. WNT can bind to Frizzled family receptor
(FZ) and pass the signal to Dishevelled (DVL) protein
inside the cell and subsequently to the β-catenin
destruction complex consisting of AXIN, APC, GSK3β
and CKIα [53, 54]. The crosstalk between
TGF-β/SMAD and WNT/β-catenin pathway mainly
occurs in the nucleus, where SMADs form a complex
with β-catenin and LEF protein to synergistically
regulate a set of genes. For example, deletion of
SMAD4 in the Müllerian duct led to reduced LEF1
signal, suggesting the alleviated WNT/β-catenin
signaling pathway [55]. Meanwhile, these two
pathways reciprocally regulate each other’s ligand
production and thus influence the pathway initiation
[56, 57]. In the cytoplasm, SMAD7 is one of the points
that link the two pathways. It is well known that
SMAD7 functions to compete with SMAD2/3 for
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receptors, which leads to ubiquitination and
degradation of receptors, and hence inhibiting
SMAD2/3 phosphorylation and activation [3].
However, SMAD7 is found to disassemble the
β-catenin destruction complex by binding to AXIN,
thus stablizing β-catenin and promoting its nucleus
translocation [56]. Meanwhile, the interaction also
leads to SMAD7 ubiquitination and degradation by
E3 ubiquitin ligase Arkadia [57]. Moreover, in the
human pancreatic adenocarcinoma cells BxPC3, in
which SMAD4 is homozigously deleted, chronic EGF
stimulation induces β-catenin phosphorylation that
can be antagonized by SMAD4 restoration, suggesting
that SMAD4 homozigous deletion is critical to EGF
induced
WNT/β-catenin
signaling
pathway
inhibition [58].

TGF-β/SMAD4 in cancer
It is a common view that cancer is a notorious
disease with an accumulation of critical genes
alteration [59]. Heterozygous or homozygous deletion
of SMAD4 was first discovered in pancreatic duct
adenocarcinoma, and later detected in various types
of cancers, such as colorectal cancer, cholangiocarcinoma, gastric cancer, prostate cancer and many others,
though with lower frequencies to some extent (Table
1). Representative SMAD4 mutations in various
cancers are summaried in Figure 3.

Pancreatic cancer
Pancreatic cancer is a lethal disease with a 5-year
survival rate of about 8%, and advance is slow for
treatment [60]. So many studies have demonstrated
that SMAD4 alteration is closely related with
pancreatic cancer since its discovery in 1996. Loss of
heterozygosity occurs in almost 60% human
pancreatic cancers, and about 50% shows homozygous deletion or intragenic inactivating mutations [5,
61]. A further study revealed that SMAD4 mutation
was associated with pancreatic pathologic stages. The
inactivation of SMAD4 was 31% (9/29) in the
high-grade stage neoplasms (Pan IN-3), while none
was found in the rest 159 low-grade lesions (Pan IN-1
and 2) [62]. Genetically engineered mouse models
have been used to investigate the mechanism (Table
3).
Although
knockout
of
SMAD4
by
pancreatic-specific PDX1-Cre or P48-Cre did not
initiate pancreatic cancer in mice [63, 64], they
markedly facilitated tumor progression initiated by
KRASG12D activation [65] or PTEN inactivation [66].
These reports favor the view that SMAD4 has a tumor
suppressive function at the progressive stage.

http://www.ijbs.com
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Figure 3. Schematic diagram of mutational pattern in exons of SMAD4. Note: SMAD4 gene contains 12 exons, 11 of which were identified at first, and
another exon was discovered later at the upstream of exon 1, so it was called exon 0. The exon 11 is about fifty times longer than exon 10, so it is labeled with dash
line.

Table 1. SMAD4 genetic alteration frequency in human cancers
Cancer type

Total alteration
frequency

Alteration type
Complete deletion Amplification Mutation
Ampullary Carcinoma
18.1% (29 cases)
18.1% (29 cases)
Bladder Urothelial Carcinoma
1.5% (4 cases)
1.1% (1 cases)
Breast Cancer
2.1% (98 cases)
0.7% (33 cases)
0.4% (17 cases) 0.5% (22 cases)
Cholangiocarcinoma
4.2% (2 cases)
4.2% (2 cases)
Colorectal Adenocarcinoma
13.2% (167 cases) 0.9% (11 cases)
12.1% (152 cases)
Desmoplastic Melanoma
10% (2 cases)
10% (2 cases)
Esophageal Adenocarcinoma
8.2% (12 cases)
8.2% (12 cases)
Esophageal Carcinoma
16.8% (31 cases) 9.8% (18 cases)
6% (11 cases)
Esophagus-Stomach Cancers
20.8% (55 cases) 10.9% (29 cases)
0.4% (1 cases) 8.3% (22 cases)
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma 4.2% (2 cases)
4.2% (2 cases)
Gallbladder Carcinoma
3.1% (1 cases)
3.1% (1 cases)
Glioblastoma
0.7% (5 cases)
0.1% (1 cases) 0.6% (4 cases)
Advanced Germ Cell Tumors
0.6% (1 cases)
0.6% (1 cases)
Hepatocellular Carcinomas
1.2% (10 cases)
0.2% (2 cases)
0.8% (7 cases)
Head and Neck Squamous Cell Carcinoma
6.2% (55 cases)
3.8% (34 cases)
2.4% (21 cases)
Recurrent and Metastatic Head & Neck Cancer
1.5% (2 cases)
1.5% (2 cases)
Kidney Cell Carcinoma
0.8% (9 cases)
0.3% (3 cases)
0.1% (1 cases) 0.5% (6 cases)
Kidney Chromophobe
1.5% (1 cases)
1.5% (1 cases)
Adrenocortical Carcinoma
1.1% (1 cases)
1.1% (1 cases)
Pan-Lung Cancer
4.5% (52 cases)
1.3% (15 cases)
0.1% (1 cases) 3.1% (35 cases)
Lung Adenocarcinoma
4.1% (33 cases)
1% (8 cases)
0.1% (1 cases) 2.5% (20 cases)

Multiple alterations
0.4% (1 cases)
0.6% (26 cases)
0.3% (4 cases)

1.1% (2 cases)
1.1% (3 cases)

0.1% (1 cases)

0.1% (1 cases)
0.5% (4 cases)

Sample
number
160
276
4728
48
1261
20
146
184
265
48
32
708
180
840
889
132
1198
65
88
1144
805
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Cancer type

Total alteration
frequency

Alteration type
Complete deletion Amplification Mutation
2.6% (19 cases)
0.7% (5 cases)
0.3% (2 cases) 1.8% (13 cases)
3.4% (3 cases)
3.4% (3 cases)
7.3% (3 cases)
7.3% (3 cases)
1.1% (1 cases)
1.1% (1 cases)
5% (2 cases)
5% (2 cases)
1.3% (4 cases)
0.3% (1 cases)
0.9% (3 cases)
4.8% (15 cases)
3.9% (12 cases)
1% (3 cases)
0.6% (1 cases)
0.6% (1 cases)
27.8% (206 cases) 6.2% (46 cases)
20.4% (151 cases)
26.1% (6 cases)
26.1% (6 cases)
1% (1 cases)
1% (1 cases)
1% (1 cases)
1% (1 cases)
1% (5 cases)
0.2% (1 cases)
0.8% (4 cases)
2.1% (36 cases)
0.9% (15 cases)
0.5% (8 cases) 0.8% (13 cases)
4.9% (3 cases)
1.6% (1 cases)
1.6% (1 cases)
10.3% (11 cases)
10.3% (11
cases)
2.5% (3 cases)
2.5% (3 cases)
10.3% (3 cases)
10.3% (3 cases)
3.4% (11 cases)
0.8% (2 cases)
3.4% (9 cases)
10.9% (99 cases) 3.7% (34 cases)
0.2% (2 cases) 6% (55 cases)
1.3% (2 cases)
0.7% (1 cases)
0.7% (1 cases)
3.7% (28 cases)
1.1% (8 cases)
0.3% (2 cases) 2.4% (18 cases)

Lung Squamous Cell Carcinoma
Small Cell Lung Cancer
NSCLC young adult patients
Mesothelioma
Oral Squamous Cell Carcinoma
Ovarian Serous Cystadenocarcinoma
Pheochromocytoma and Paraganglioma
Pancreatic cancer
Acinar Cell Carcinoma of the Pancreas
Pancreatic Neuroendocrine Tumors
Pediatric Ewing Sarcoma
Prostate Cancer
Prostate Adenocarcinoma
Prostate Adenocarcinoma, Metastatic
Neuroendocrine Prostate Cancer
Skin Cutaneous Melanoma
Cutaneous squamous cell carcinoma
Sarcoma
Stomach Adenocarcinoma
Testicular Germ Cell Cancer
Uterine Carcinoma

Multiple alterations

1.2% (9 cases)

1.6% (1 cases)

0.9% (8 cases)

Sample
number
733
139
41
87
40
316
311
162
740
23
98
105
501
1678
61
107
121
29
450
910
149
751

Modified from http://www.cbioportal.org/index.do.

Table 2. Examples of the studies on SMAD4 and prognosis in pancreatic duct adenocarcinoma.
Number
of
samples
45

Sex
(female/
male)
18/27

Age

25
249

12/13
110/139

34

12/22

89

46/43

54.6
65.4 ±
10.5
55.2 ±
11.3
65.3
±10.5

61

Stage
Margin
(I-II/III-IV) (negative/
positive)
NS
25/20

N
(N0/ N1)

Differentiation
(well+moderate/poor)

P
value

33/12

SMAD4
Median survival
(negative/positive) (months, SMAD4
negative/positive)
35/10
6.4/13.6

24/21

10/15
59/190

22/3
168/80

19/6
NS

18/16

NS

NS

58/31

Reference

25/1
NS

8/17
138/111

5/10
14.7/19.2

0.001
0.03

[118]
[110]

20/14

NS

8/26

6.9/10.6

0.879

[119]

18/71

55/34

40/49

11.5/14.2

0.006

[120]

0.0257 [109]

Table 3. Examples of SMAD4-deficient mouse models.
Tissue type
Germline knockout
Homozygous Deletion

Cre

SMAD4 status

Combined mutation

Phenotypes

Reference

_
_
_

SMAD4-/SMAD4+/SMAD4+/-

_
_
APC+/-

Embryonically lethal
Gastric and duodenal Polyps
Intestinal Tumorigenesis

[77]
[77, 78]
[79]

PDX1-Cre
PDX1-Cre
Pancreatic progenitor cells
PDX1-Cre
P48-Cre
Pancreatic exocrine progenitor P48-Cre
ALB-Cre
Hepatocytes and bile duct
ALB-Cre
epithelial cells
PB-Cre4
Prostate epithelial cells
PB-Cre4

SMAD4co/co
SMAD4co/co
SMAD4co/co
SMAD4co/co
SMAD4+/co
SMAD4co/co
SMAD4co/co

_
KRASG12D
PTENco/co
KRASG12D
KRASG12D
_
PTENco/co

No obvious phenotype in pancreas
IPMN
Accelerated tumor formation
Enhanced IPMN development
Mucinous cystic neoplasm
Increased iron accumulation in the liver
Intrahepatic cholangiocellular carcinoma

[65]
[65, 121]
[66]
[65]
[122]
[123]
[67]

SMAD4co/co
SMAD4co/co

_
PTENco/co

[83]
[83]

Epidermis and hair follicles

MMTV-Cre

SMAD4co/co

_

Mammary epithelial cells
Esophageal and forestomach
epithelia

MMTV-Cre
K5-Cre

SMAD4co/co
SMAD4co/co

_
_

K5-Cre

SMAD4co/co

PTENco/co

LGR5-CreERT2

SMAD4co/co

PTENco/co

No prostate neoplasia
Accelerated progression and metastasis to lymph
nodes and lung
Hair follicle defects and squamous cell carcinoma
formation
Breast squamous cell carcinoma
19% of mice developed forestomach squamous cell
carcinoma by 4 months
All mice developed forestomach squamous cell
carcinoma by 2 months
Invasive intestinal-type gastric cancer by 3 months

Heterozygous Deletion
Tissue-specific knockout

Gastric LGR5+ stem cells

[86, 87]
[124]
[88]
[88]
[89]
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Cholangiocarcinoma
Cholangiocarcinoma is a type of liver cancer
originating from the bile duct. Although its prognosis
is poor compared with that of hepatocellular
carcinoma, few studies exist to address the molecular
mechanism. SMAD4 has been regarded as a tumor
suppressor in cholangiocarcinoma [67]. Loss of
SMAD4 was noted in 19 of 42 (45.2%) cases with
intrahepatic cholangiocarcinoma (ICC), and had a
positive correlation with clinical stages (25% negative
in stage I and II vs. 58% in stage III and IV) [68].
Additionally, loss of SMAD4 was inversely related
with its prognosis [69]. Hepatolithiasis is commonly
regarded as a risk factor for cholangiocarcinoma. One
group examined SMAD4 deletion frequency in the
normal intrahepatic bile duct (IHD), stone-containing
IHD and ICC, with the result of 0% (0/24), 4.4%
(2/46) and 33.3% (3/9) respectively, suggesting that
loss of SMAD4 promotes transition from IHD to ICC
[70]. However, tissue-specific deletion of SMAD4
along in mouse hepatocytes and bile duct epithelial
cells did not cause discernable tumor formation. But
homozygous deletion of both SMAD4 and PTEN in
mouse liver induced intrahepatic cholangiocarcinoma
[67]. Underlining the phenotype, PTEN and SMAD4
regulate each other through a negative feedback loop,
therefore they can compensate each other’s deletion.
So far, little is known about the mechanism of SMAD4
in cholangiocarcinoma and more research studies
examining this are required.

Colorectal cancer
The role of SMAD4 in colorectal cancer is similar
to that in pancreatic cancer and cholangiocarcinoma.
Accumulation of evidence has confirmed that the loss
of SMAD4 in colorectal cancer occurs at a frequency of
about 30% [71]. Royce et al examined SMAD4
expression by immunohistochemistry and RT-PCR in
109 patients with early-onset colorectal cancer, and
detected 27 cases (accounting for 25%) had SMAD4
loss [72]. A study on colon cancer cell lines HCT116
and SW620 demonstrated TGF-β administration could
activate ERK and P38 pathways and induce VEGF
overexpression when SMAD4 was knocked down
[73]. In addition, the SMAD4 loss was responsible for
resistant to 5-fluoruracil mediated apoptosis in these
two cell lines [73]. The rate of SMAD4 loss has a
positive
correlation
with
colorectal
cancer
progression, convincing that inactivation of SMAD4 is
a late event in colorectal carcinogenesis [74, 75].
Although germline loss of SMAD4 in human [76] or
heterozygous deletion in mice [77, 78] caused juvenile
polyposis (JP), the risk of carcinoma is low and
associated with a long latency, suggesting that
SMAD4 loss alone may be insufficient for tumor
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initiation. It has been reported that heterozygous
deletion of SMAD4 promotes progression of
colorectal cancer initiated by germline mutation of
APC [79]. SMAD4 status is also correlated with tumor
microenvironment.
SMAD4-deficient
colorectal
tumor cells secreted more CCL9 and CCL15,
chemokines that recruit CCR1+ myeloid cells through
CCL9-CCR1 and CCL15-CCR1 axis, leading to
metastasis [80, 81]. Moreover, deletion of SMAD4 in
human colorectal tumor cells reduced the number of
S100A8-positive monocytes and attenuated the
sensitivity of tumor cells to chemokine S100A8,
suggesting the effect of SMAD4 on monocyte infiltrate
[82].

Other cancers
SMAD4 loss occurs prevalently in above
mentioned types of cancers and many other cancers
with lower frequencies (Table 1). Similar to pancreatic
and intrahepatic cholangiocarcinoma, prostate
specific deletion of SMAD4 did not initiate cancer
formation, but synergistically promotes tumorigenesis together with PTEN deletion [83]. SMAD4
mutations are rare in human prostate cancer, but
SMAD4 promotor methylation is commonly detected,
which may reduce SMAD4 expression [84]. Of note,
SMAD4 downregulation was found at an early stage
in human HNSCC, and deletion of SMAD4 alone in
murine head and neck epithelia results in
spontaneous HNSCC that mimics human HNSCC
[85]. Keratinocyte-specific deletion of SMAD4 results
in predominantly well-differentiated skin tumors,
revealing that SMAD4 is a tumor initiator [86]. A very
similar phenotype is obtained in the mouse mammary
tumor virus (MMTV)-Cre mediated SMAD4 deletion
[87]. In these types of cancers, SMAD4 loss occurs
prior to tumor formation, and disrupts DNA repair
mechanisms to enhance genomic instability and
inflammation [85]. It was also reported that mice
carrying K5-Cre mediated deletion of SMAD4 in
keratinocytes developed forestomach squamous cell
carcinoma (SCC) at 8 months, while deletion of PTEN
only suffered dysplasia. However, concurrent
deletion of SMAD4 and PTEN led to invasive SCC in 2
months [88]. Moreover, deletion of SMAD4 and PTEN
by LGR5-Cre drived gastric LGR5+ stem cells
transformation, thus causing invasive intestinal-type
gastric cancer [89]. In the gastric cancer cell lines
MGC-803 and BGC-823, SMAD4 serves as the direct
target of miR-324-3p, which promotes gastric cancer
progression. This miR-324-3p induced tumor growth
can be rescued by restoration of SMAD4 [90]. These
data prompt us to conclude that the role of SMAD4 on
cancer initiation may be cancer type-dependent (Table
3).
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TGF-β/SMAD4 in
epithelial-mesenchymal transition
Epithelial-mesenchymal transition (EMT) is a
well-coordinated process that epithelial cells lose their
cell junctions and polarity, and are transformed to
mesenchymal cells with the migratory and invasive
abilities [91]. Molecularly, this process is accompanied
with the cell junction switch from E-Cadherin to
N-Cadherin [92, 93]. TGF-β signaling is known as an
important molecule to induce EMT in a
SMAD4-dependent manner through the induction of
translocation of SMAD2/3/4 complex to the nucleus,
leading to the expression of mesenchymal markers
SNAIL, SLUG, TWIST and ZEB [94-96]. When
knocking down SMAD4 in mammary gland epithelial
cell NMuMG, the TGF-β induced EMT was potently
blocked with the failure of E-cadherin reduction and
N-cadherin induction, as well as morphologic
transformation [97]. Similarly, SMAD4 knockdown in
liver significantly reduced liver tumorigenesis
through upregulating SNAIL, suggesting that TGF-β
signal promotes EMT in a SMAD4-dependent manner
[98]. Moreover, TGF-β induced EMT is also inhibited
by the nuclear factor YY1, which can bind to SMAD
complex and suppress its transcriptional activity [99,
100]. These reports reinforce the role of SMAD4
mediated TGF-β signal in the EMT process. A recent
study revealed that TGF-β/SMAD4 signal also
inhibits the transcription of KLF5 through SNAIL.
With the low KLF5 level, SOX4 is switched from
tumor
promotor
to
suppressor.
Therefore,
TGF-β/SMAD4 actually induced lethal EMT in PDAC
[101].

TGF-β/SMAD4 in DNA damage response
and DNA damage repair
It has been shown that mice carrying specific
disruption of SMAD4 in head and neck epithelia
developed head and neck cancer that is associated
with increased genomic instability and downregulated expression and function of genes encoding
proteins in the Fanconi anemia/BRCA (FANC/
BRCA) DNA repair pathway [85]. It was also shown
mice carrying K14-Cre mediated disruption of
SMAD4 (K14.SMAD4-/-) in keratinocytes suffered
increased DNA damage and increased susceptibility
to UV induced carcinogenesis [102]. The skin of the
K14.SMAD4-/- mice had significantly reduced
expression of excision repair cross-complementation
group1 (ERCC1) gene that is correlated with reduced
ERCC1-mediated DNA repair. Their further study
demonstrated that SMAD4 deficiency impaired
SNAIL binding to the ERCC1 regulatory elements,
leading to the reduced ERCC1 expression. In breast
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cancer cells and primary breast tumor specimens, it
was found that TGF-β downregulates the expression
of several genes that are essential for DNA damage
response (DDR), including ataxia telangiectasiamutated (ATM), mutS homolog 2 (MSH2), and
BRCA1 [103, 104]. Through downregulating these
genes, TGF-β
attenuates
DDR in
these breast
cancer cells and enables them to escape the DNA
damage checkpoint, allowing their proliferation in the
presence of unrepaired DNA damage. Thus,
TGF-β/SMAD4 signaling plays an important role in
maintaining DDR and DNA damage repair through
regulating transcription and activity of some key
genes involved in these processes. This may be one of
the main mechanisms through which TGF-β/SMAD4
signaling suppresses tumor formation and growth.

TGF-β/SMAD4 and microRNA
Recent studies revealed that another important
function of TGF-β/SMAD4 signaling is in regulation
of microRNA. It has been shown that TGF-β1 was able
to induce miR-574-3p transcription in gastric cancer
cell AGS to inhibit cell proliferation, which was
dependent on the binding of SMAD4 to the promotor
of miR-574-3p [105]. Moreover, TGF-β/SMAD4
signaling could induce a set of microRNAs in human
hepatocellular carcinoma cell Huh-7. The transcription of miR-23a∼27a∼24 was upregulated quickly
upon TGF-β treatment, and attenuated by SMAD4
deletion [106]. On the other hand, SMAD4 is also
subject to regulation by microRNA. In colon cancer
cells and tumor specimens, the upregulated
miR-19b-3p directly targets SMAD4 to attenuate
proliferation and sensitivity to oxaliplatin-based
chemotherapy [107]. Besides miR-19b-3p, SMAD4 is
also the target of some other microRNAs. For
example, miR-27a, which is induced in human
lymphatic endothelial cells (HLECs) by co-culturing
with colon tumor cells, directly targetes SMAD4 and
promotes lymphangiogenesis [108].

TGF-β/SMAD4 and cancer prognosis
Although the molecular mechanism of SMAD4
in carcinogenesis is still not clear, the alteration in
types of cancers are studied exclusively, especially in
pancreatic adenocarcinoma (Table 2). Wilentz et al
(2000) studied 41 xenografted primary periampullary
adenocarcinomas for the correlation between SMAD4
expression and prognosis [109]. Immunohistochemical staining of SMAD4 showed 22 cases were
negative, accounting for 56% of the patients. The
survival analysis revealed that the patients with
positive SMAD4 signal lived longer than those with
negative signal, with the median survival of 16.5
months versus 9 months. Recently, Singh’s group
http://www.ijbs.com
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focused on an Indian population with pancreatic duct
adenocarcinoma for SMAD4 alteration and effect of
its loss on patient survival [110]. The SMAD4 gene
was altered by homozygous deletion in 5 patients and
intragenic mutation in the MH2 domain in 3 patients,
together accounting for 32% of the patients. The
follow-up investigation provided a median survival
of 5 months in the SMAD4 alteration group while 10
months in the SMAD4 wildtype group. Many other
reports, as summarized in table 2, show the similar
outcome in pancreatic duct adenocarcinoma.
SMAD4 expression level has a positive
correlation with survival in colon cancer, and the loss
of SMAD4 leads to poor prognosis [111].
Additionally, SMAD4 is also correlated with tumor
metastasis [112]. A study involving 202 colorectal
cancer patients revealed that cases with normal
SMAD4 expression benefit from 5-ﬂuorouracil based
chemotherapy at a 3-fold higher improvement than
those with SMAD4 loss [113]. These studies suggest
that SMAD4 loss may predict poor outcome for
5-ﬂuorouracil therapy in patients with colorectal
cancer.
Recent studies indicated that SMAD4 could be a
prognostic factor together with other genes. Through
evaluating the expression level of SMAD4 and PTEN
in patients bearing colorectal cdenocarcinoma, there
was a significant difference in the overall survival,
showing patients with loss of both SMAD4 and PTEN
had worse outcome than cases with SMAD4 or PTEN
loss alone [114]. Moreover, another study showed the
patients with wildtype SMAD4 and KRAS had twice
longer survival than those bearing SMAD4 loss and
KRAS actication (83.8 vs. 36.7 months) [115].

Conclusion and perspective
Numerous studies during passed two decades
provide strong evidence that SMAD4 is a tumor
suppressor, whose mutations are found in at least 26
types of cancer, with higher frequencies in GI tract
cancers, such as Esophagus, Stomach, pancrease and
Colorectal cancers (Table 1). Additionally, loss of
SMAD4 in tumors affects cancer progression and
therapy, such as reduced response to adjuvant
chemotherapy [116]. SMAD4 plays its function
through acting as the central mediator for canonical
TGF-β signaling pathway, and affects tumorigenesis
through numerous mechanisms, such as inducing cell
cycle arrest, apoptosis, EMT, and others. Thus,
SMAD4 not only functions as a tumor suppressor, but
also may serve as a prognostic indicator.
Even though the SMAD4 mediated TGF-β
signaling pathway has been elucidated well, how
SMAD4 alteration causes tumor formation and
progression remains unclear due to the crosstalk with
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other pathways. For example, although SMAD4 is
highly deleted in human pancreatic cancer, the mouse
with SMAD4 deficiency in pancreas dose not develop
a tumor, suggesting additional mutations may be
required. Owing to the technology limitation, only a
few genes, such as APC in colorectal cancer and PTEN
in pancreatic cancer and cholangiocarcinoma, are
currently identified. Fortunately, the recent
well-developed CRISPR knockout library provides
the opportunity to screen these SMAD4 synergistic
genes at genome-scale level. Therefore, we can
anticipate the discovery of more such genes.
Moreover, the CRISPR knockout library can also be
used to screen drug resistant or sensitive genes on the
genetic background of SMAD4 deficiency, as the
SMAD4 loss is reported to predict poor outcome for
chemotherapy, such as 5-ﬂuorouracil therapy in
patients with colorectal cancer [113].
Although limited knowledge is availabale
regarding the mechanism, some molecules associated
to SMAD4, including UA62001 and UA62784, have
been developed as candidates in cancer treatment [71,
117]. With the discovery of new components that
could facilitate SMAD4 associated tumor progression
and resistant genes in SMAD4 associated insensitivity
to drugs, more and more SMAD4 associated
molecules can be the potent target for cancer
treatment.
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